Newsletters


Filter by volume

Agenus on Twitter

This year, we look forward to accelerating development of our pipeline to broaden the reach of immunotherapies to more patients & tumor types. @omalleygynonc highlights the durable responses induced by our CTLA-4 antibody candidates in many GYN cancers: targetedonc.com/view/sitc-2021…

Bal/Zal Phase 2 cervical cancer trial results published in Journal of Clinical Oncology; 26% ORR (33% ORR in PD-L1+ patients), mDoR not reached after 21 months of follow-up. Click here to read more: investor.agenusbio.com/news-releases/…

$AGEN has been named to the Boston Business Journal’s list of 2021 Middle Market Leaders, their 50 highest growth middle-market companies in MA. We are thrilled to be nominated and look forward to further growth and progress next year. @BosBizJournal bizjournals.com/boston/news/20…

Rottapharm Biotech Clinical Collaboration: An important step for treatment-resistant colorectal cancer The 1st patient has been dosed in their Ph 1/2 study of CR6086 combined with balstilimab in advanced CRC. Read the latest $AGEN newsletter here: agenusbio.com/newsletters/ag…

@dhanschand, $AGEN Scientific Director Head of Drug Discovery, is speaking today at the 2nd Annual TIGIT Therapies Digital Summit on the panel session “Fc binding for Effector Function: What have we Learnt?” Register to watch at 12:30 PM ET! tigit-therapies.com/speaker/dhan-c…

test Twitter Media - @dhanschand, $AGEN Scientific Director Head of Drug Discovery, is speaking today at the 2nd Annual TIGIT Therapies Digital Summit on the panel session “Fc binding for Effector Function: What have we Learnt?” Register to watch at 12:30 PM ET! 

https://t.co/BBAKlXVLGi https://t.co/3rv3r8uhTv

Tune in today at 1:50PM ET for our fireside chat by @garo_armen and @ODayMD at the annual Evercore ISI HealthCONX Conference: wsw.com/webcast/everco…

The latest Agenus Newsletter is now available! AGEN1181 Achieves Responses Across 9 Cancers: Seventeen Objective Responses as Single Agent or in Combination with Balstilimab agenusbio.com/newsletters/ag…

Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 investor.agenusbio.com/events/event-d…

test Twitter Media - Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 

https://t.co/wB0kWxRkkG https://t.co/yO0D7n2Al0

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 investor.minktherapeutics.com/news-releases/… #SITC21 Retweeted by Agenus Inc. ($AGEN)

Hear @ODayMD and @DrMhidalgo discuss the latest #AGEN1181 Phase 1 data from #SITC21 in a webcast hosted by William Blair. investor.agenusbio.com/events/event-d…

test Twitter Media - Hear @ODayMD and @DrMhidalgo discuss the latest #AGEN1181 Phase 1 data from #SITC21 in a webcast hosted by William Blair.

https://t.co/hGVeLeXHNH https://t.co/AbqrGVZ8Yn

Our #SITC21 abstract summarizing #AGEN1181 data from >100 patients treated is live! #AGEN1181 +/- balstilimab shows durable responses in 9 cancer types, including patients who have failed PD-1 therapy; Ph2/3 to commence in colorectal and GYN cancers. jitc.bmj.com/content/9/Supp…

See $AGEN full Q3 2021 earnings report and corporate update here: investor.agenusbio.com/news-releases/…

Today, we took another step in advancing our immuno-oncology therapies to cancer patients. We announced that the first patient has been dosed with AGEN1777, our first-in-class #TIGIT bispecific licensed to @bmsnews, triggering a $20M milestone payment. investor.agenusbio.com/news-releases/…

WHO recommends broader use of the world’s first malaria vaccine, containing Agenus’ QS-21 Stimulon. Read today’s story from @BosBizJournal. @garo_armen bizjournals.com/boston/news/20…

Yesterday, @WHO rec. widespread use of the 1st malaria vaccine to young children in sub-Saharan Africa —what made the news more interesting was the fact that it was a 27-yr old biotech in Lexington that made the vaccine possible. @garo_armen @Agenus_Bio bit.ly/2YvXHgk Retweeted by Agenus Inc. ($AGEN)

Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology

test Twitter Media - Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology https://t.co/CmNwfKJAB8

Targeting ILT-4 with $AGEN discovered antibody, MK-4830, may increase the anti-tumor activity of pembrolizumab even in tumors with low levels of T-cell inflammation. Publication in Clinical Cancer Research discusses potential of ILT-4 blockade to abrogate PD-1/PD-L1 resistance twitter.com/CCR_AACR/statu…